MORGAN STANLEY PLC/PUT/VERTEX PHARMACEUTICALS/350/0.01/20.09.24

MORGAN STANLEY PLC/PUT/VERTEX PHARMACEUTICALS/350/0.01/20.09.24 Share Price

DE000ME4MQE4

Real-time Bid/Ask 02:34:57 05/07/2024 pm IST
0.041 ^EUR / 0.056 ^EUR	+28.95%

Current month	-15.56%
1 month	-22.45%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart MORGAN STANLEY PLC/PUT/VERTEX PHARMACEUTICALS/350/0.01/20.09.24

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis	02/07	MT
Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy	02/07	DJ
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis	02/07	BU
Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, A Next-In-Class Triple Combination Treatment for Cystic Fibrosis	02/07	CI

More news

Quotes 5-day view

Date	Price	Change
05/24/05	0.042	+10.53%
04/24/04	0.038	-11.63%
03/24/03	0.043	0.00%
02/24/02	0.043	-4.44%
01/24/01	0.045	0.00%

Delayed Quote Börse Stuttgart

Last update July 05, 2024 at 12:46 pm IST

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	PUT
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	Morgan Stanley
WKN	ME4MQE
ISIN	DE000ME4MQE4
Date issued	05/12/2023
Strike	350 $
Maturity	20/09/2024 (78 Days)
Parity	100 : 1
Emission price	0.34 €
Emission volume	N/A
Settlement	Barausgleich
Currency	EUR

Technical Indicators

Highest since issue	0.34 €
Lowest since issue	0.038 €
Spread	0.021 €
Spread %	35.00%

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

470.3 USD

Average target price

468.3 USD

Spread / Average Target

-0.43%

Consensus